Theravance Biopharma (NASDAQ:TBPH) Stock Crosses Above 50-Day Moving Average – Time to Sell?

Theravance Biopharma, Inc. (NASDAQ:TBPH)’s share price passed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $16.42 and traded as high as $16.57. Theravance Biopharma shares last traded at $16.49, with a volume of 332,098 shares.

Analysts Set New Price Targets

TBPH has been the topic of a number of recent analyst reports. Weiss Ratings cut shares of Theravance Biopharma from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday, May 27th. Zacks Research raised shares of Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a research report on Thursday, March 19th. Wall Street Zen downgraded shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. Oppenheimer lowered shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating in a report on Thursday, March 5th. Finally, BTIG Research reaffirmed a “buy” rating and set a $21.00 price target on shares of Theravance Biopharma in a research report on Friday, March 20th. Two investment analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $21.83.

Theravance Biopharma Stock Up 1.2%

The firm has a market cap of $850.06 million, a PE ratio of 7.50 and a beta of 0.17. The stock has a 50 day moving average price of $16.42 and a two-hundred day moving average price of $17.50.

Theravance Biopharma (NASDAQ:TBPH) last announced its quarterly earnings data on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) EPS for the quarter. The company had revenue of $17.70 million during the quarter. Theravance Biopharma had a net margin of 104.34% and a return on equity of 18.84%. As a group, equities analysts anticipate that Theravance Biopharma, Inc. will post 1.58 earnings per share for the current year.

Insider Activity

In other Theravance Biopharma news, SVP Rhonda Farnum sold 31,067 shares of the firm’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $13.96, for a total value of $433,695.32. Following the completion of the transaction, the senior vice president owned 232,699 shares of the company’s stock, valued at approximately $3,248,478.04. This trade represents a 11.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 7.65% of the company’s stock.

Hedge Funds Weigh In On Theravance Biopharma

Several hedge funds have recently made changes to their positions in the company. Bank of America Corp DE raised its stake in Theravance Biopharma by 78.2% in the 1st quarter. Bank of America Corp DE now owns 189,155 shares of the biopharmaceutical company’s stock worth $3,070,000 after acquiring an additional 82,978 shares during the last quarter. California State Teachers Retirement System raised its stake in shares of Theravance Biopharma by 1,649.4% in the first quarter. California State Teachers Retirement System now owns 40,761 shares of the biopharmaceutical company’s stock worth $662,000 after purchasing an additional 38,431 shares during the last quarter. Empowered Funds LLC acquired a new stake in shares of Theravance Biopharma during the first quarter worth about $900,000. Quantinno Capital Management LP lifted its holdings in shares of Theravance Biopharma by 32.9% during the first quarter. Quantinno Capital Management LP now owns 18,038 shares of the biopharmaceutical company’s stock worth $293,000 after purchasing an additional 4,463 shares during the period. Finally, Rangeley Capital LLC purchased a new stake in Theravance Biopharma in the first quarter valued at approximately $1,672,000. 99.10% of the stock is owned by institutional investors and hedge funds.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.